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   The value of clinical use of tumor markers CEA and CA15-3 for early detection of recurrent breast 
cancer still is a controversial. This study was investigated relationship between tumor markers CEA and 
CA15-3 and recurrence breast cancer. Data regarding 147 women who had breast cancer were entered 
into the study. Patients were reviewed for 120 months after treatment. Maximum time for relapse was 
considered a 6 months. Results were showed recurrence cancer in 20% of diagnosed patients. All of 
them in diagnosis time had a higher of normal tumor markers (CA<3, CA15-3<30).These observations 
indicated that CA15-3 is a sensitive tumor marker for diagnosis especially for recurrent breast cancer. 
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INTRODUCTION 
     Breast cancer is the most common female- 
related cancer that leads to death in the mostly 
women worldwide [1]. As a normal cell 
transforms to a neoplastic cell, changes occur 
both within and on the surface of the cell that 
could potentially be detected and used as a 
tumor marker. This could provide valuable 
information on the status of the cell at the given 
point thus enabling early detection, which is key 
to cancer cure and prevention [2,3]. Recurrence 
of cancer after the diagnosis is unavoidable 
issues. To prevent or reduce relapse, various 
treatments including surgery, chemotherapy, 
radiotherapy and other treatments are applied. 
But one of the tools for the diagnosis of breast 
cancer and predict recurrence are tumor 
markers. However, the predictive value of 
tumor markers in prediction of disease 
recurrence is controversial. Tumor markers in 
breast cancer are extremely various in number 
and type. Mucins e.g. CA15.3 [4,5].and CA 27-
29 [6]. , oncofoetal proteins (e.g. CEA) [7,8]., 
oncoproteins e.g. HER2 [9-11]. c-myc [12]. and 
p53 [14,15].,cytokeratins e.g. TPA [16,17].and 
ESR [18-20]. are among the many proposed as a 
tumour marker for breast cancer. More recent 
tumour markers described in the literature 
include Mammaglobin [21]., survivin [22,23., 
livin [24]., NYESO- 1 [25]., Annexin XI-A 
[26]., Endostatin [27]., Hsp90 [28]., p62 [29]. 
and koc [30]. In this study, we investigate 
relationship between tumor markers CEA and 
CA15-3 to Breast cancer recurrence for patients 
in west mazandaran 
 
MATERIALS AND METHODS 
     In this study–retrospective, Women with 
breast cancer were studied in West Mazandaran 
with tumor markers CEA and CA15-3, and 
recurrence was evaluated. Recurrence was 
defined as reappearance of symptoms after a 
period of free of the disease in the clinical 
examination or diagnostic procedure (In this 
study, CEA <3 and CA15-3 <30 as normal was 
considered). Patients were followed for 120 
months, Mean age in the age range 24 to 80 
Years. 51.3%, patients in stage Ⅰ,Ⅱ and 46.9% 
of patients with stage Ⅲ and Ⅳ of disease. 
95.2% of patients undergoing complete 
resection of breast and 4.8% of patients were 
removed part of their breast. Demographic data 
were recorded in the corresponding checklist. 
The data's after coding were analyzed by 
statistical software (SPSS 18). 
Patients who did not complete their records and 
those records were not recorded tumor marker 
in diagnosis process, were excluded. 
  






     Follow up of 147 Patients, with to 
measurement of the CEA, CA15-3 markers in 
relapsed them 20%. The tables 1 and 2 show the 
abundance of patients with breast cancer 
recurrence compared with patients without 
recurrence based on Status of CA15-3 and CEA 
markers. The result of obtained from Fisher's 
Exact Test show that were obtained Significant 
relationship between recurrence cancer and 
Status of CA15-3 markers, but statistical 
analysis show CEA is a low sensitivity markers 
obtained Significant relationship between 
recurrence cancer. Also, were not obtained 
significant relationship between recurrence 
cancer and duration, multiplicity of 
chemotherapy in the patients that, shows in the 
table 3.   
 




Normal  High  
Abundance % Abundance % Abundance % 
Recurrence 
cancer 
Yes 4 14.3 24 85.7 28 100 
No 107 89.9 12 10.1 119 100 
All 111 75.5 36 24.5 147 100 
* p-value : 0.0001, Fisher's Exact Test 
 





Abundance % Abundance % Abundance % 
Recurrence 
cancer 
Yes 14 50 14 50 28 100 
No 95 79.8 24 20.2 119 100 
All 109 74.1 38 25.9 147 100 
* p-value: 0.003, Fisher's Exact Test 
 
Table 3. The abundance, mean ,  minimum , maximum of  CEA ، CA15-3  ، markers , duration  and multiplicity of chemotherapy in  




Abundance mean minimum maximum p-value 
CEA 
yes 28 11.4 0.2 94.7 
0.0001 No 119 2.2 0.1 15.60 
All 147 3.9 0.10 94.7 
CA15-3 
yes 28 74.5 13.5 319.1 
0.0001 No 119 22.3 1.96 223 




     Molina and colleagues reported that only 
13% of patients with primary breast cancer had 
an elevated serum CEA whilst 18.8% had a rise 
in CA15.3 [31]. 
In a study in 2010 by Samy and et al [32]. in 
Egypt, 81 patients with breast cancer (Stage Ⅰ, 
Ⅱ) were enrolled. 
All patients underwent mastectomy or 
canserative treatment. Recurrence was observed 
in 9 patients followed for 18 months. The CEA 
and CA15-3 levels significantly higher in 





Lumachei and et al [33] in 2010, 362 women 
with breast cancer who had undergone surgery 
were followed for at least 36 months. 
During follow up 62 patients (1/17 percent) 
relapsed. In this study the authors concluded 
that CA15-3 and CEA markers are  acceptable 
factors for recurrence predicting at the time of 
diagnosis , but in older women (above 64 
years), initial levels of tumor markers in 
recurrence predicting is not applicable. 
Mariani and et al [34] studied 900 patients with 
breast cancer and was evaluated sensitivity and 
specificity of different tumor markers for distant 
recurrence. In this study the authors concluded 





CA15-3 and CEA markers is weakly effective 
in distant recurrence. 
Lumachi and et al [35], reported, in patients 
with breast cancer, serum markers CEA and CA 
15-3 correlate exclusively with the size of the 
tumor. Both have low sensitivity and no 
significant relationship with other prognostic 
factors could be found. Thus, preoperative CEA 
and CA 15-3 serum levels measurements are of 
little value, especially in patients with early-
stage breast cancer, and are not useful in the 
therapeutic decision-making for patients with 
breast cancer. Prabasheela and et al [36], 
reported CA 15-3 is a well established tumor 
marker for early detection of recurrent breast 
cancer. They were investigated Blood samples 
for CA 15-3 level in 50 histopathologically 
proven breast cancer patients of which 30 
patients are untreated and 20 had under gone 
primary surgery in comparison with 50 normal 
healthy persons (control) of similar average age 
limit and body mass. Serum levels of CA 15-3 
were significantly in breast cancer patient (p 
<0.05). 
Berberoglu and et al [37], indicated that CA 15-
3 is a sensitive tumor marker for diagnosis and 
especially for monitoring of breast cancer 
patients.  In this study, patients with breast 
cancer and high tumor marker CA15-3 have 
shown a higher recurrence. 
 
CONCLUSION  
     The existence of an independent factor for 
tumor markers CA15-3 at the time of diagnosis 
and the results from this study showed in the 
incidence of recurrence.  
Important results of this study is that perhaps 
can be predicted the risk of recurrence in 
patients only a measurement of CA15-3 and 
CEA markers, especially CA15-3 at the time of 
diagnosis and will design treatment plan of 
these patients for recurrence reducing from the 
early stages. To prove this relationship, and 
according to inconsistent and similar studies 
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